The Underutilization of Pramlintide as Adjunct Therapy in Type 1 and Type 2 Diabetes

Hieronymus L Griffin S . Role of amylin in type 1 and type 2 diabetes. Diabetes Educ. 2015;41(1 suppl):47S-56S. doi:10.1177/0145721715607642

McQueen J . Pramlintide acetate. Am J Health Sys Pharm. 2005;62(22):2363-2372. doi:10.2146/ajhp050341

American Diabetes Association Professional Practice Committee. 9: Pharmacologic approaches to glycemic treatment: Standards of Medical Care-2022. Diabetes Care. 2022;45(suppl 1):S125-S143. doi:10.2337/dc22-S009

Handelsman Y Bloomgarden Z Grunberger G , et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015:21(suppl 1):1-87. doi:10.4158/EP15672.GL

Edelman S Garg S Frias J , et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes. Diabetes Care. 2006;29(10):2189-2195. doi:10.2337/dc06-0042

Singh-Franco D Perez A Harrington C . The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011;13(2):169-180. doi:10.1111/j.1463-1326.2010.01337.x

Symlin. Package insert. AstraZeneca Pharmaceuticals LP; 2014.

Pramlintide. In: Lexi-drugs Online [database on the Internet]. Hudson (OH): Lexicomp Inc.; 2022 [cited 29 Mar 2022]. Available from: http://online.lexi.com. Subscription required to view.

Pullman J Darsow T Frias J . Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes. Vasc Health Risk Manag. 2006;2(3):203-212. doi:10.2147/vhrm.2006.2.3.203